Tumor microenvironment in renal cell carcinoma: what is the current impact?

Papers of special note have been highlighted as: •• of considerable interest

References

• 1. Rizzo A, Rosellini M, Marchetti A, Mollica V, Massari F. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy 13(8), 685–692 (2021).
  CASGoogle Scholar
• 2. Wang Q, Shao X, Zhang Y et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 12(10), 11149–11165 (2023).
  MedlineGoogle Scholar
• 3. Guida A, Sabbatini R, Gibellini L, De Biasi S, Cossarizza A, Porta C. Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: what are we looking for? Cancer Treat. Rev. 94, 102157 (2021).
  Medline CASGoogle Scholar
• 4. Braun DA, Street K, Burke KP et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632–648.e8 (2021).
  Medline CASGoogle Scholar
• 5. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).
  Medline CASGoogle Scholar
• 6. Koh MY, Sayegh N, Agarwal N. Seeing the forest for the trees – single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer. Cancer Cell 39, 594–596 (2021).
  Medline CASGoogle Scholar
• 7. Turajlic S, Xu H, Litchfield K et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell 173, 581–594.e12 (2018).
  Medline CASGoogle Scholar
• 8. Clark DJ, Dhanasekaran SM, Petralia F et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell 179, 964–983.e31 (2019). •• Reports a large-scale proteogenomic analysis of clear cell renal cell carcinoma (ccRCC) to discern the functional impact of genomic alterations and provides evidence for rational treatment selection based on ccRCC pathobiology.
  Medline CASGoogle Scholar
• 9. Şenbabaoğlu Y, Gejman RS, Winer AG et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17(1), 231 (2016).
  MedlineGoogle Scholar
• 10. Zhang S, Zhang E, Long J et al. Immune infiltration in renal cell carcinoma. Cancer Sci. 110, 1564–1572 (2019).
  Medline CASGoogle Scholar
• 11. Raimondi A, Sepe P, Zattarin E et al. Predictive biomarkers of response to immunotherapy in metastatic renal cell cancer. Front. Oncol. 10, 1644 (2020).
  MedlineGoogle Scholar
• 12. Chevrier S, Levine JH, Zanotelli VRT et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749.e18 (2017).
  Medline CASGoogle Scholar
• 13. Verbiest A, Renders I, Caruso S et al. Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors. Clin. Genitourin. Cancer 17, e981–e994 (2019).
  MedlineGoogle Scholar
• 14. Beuselinck B, Job S, Becht E et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res. 21, 1329–1339 (2015). •• Identifies the ccRCC molecular subtypes that are predictive of sunitinib response in metastatic patients and could be used for personalized metastatic renal cell carcinoma treatment.
  Medline CASGoogle Scholar
• 15. Beuselinck B, Verbiest A, Couchy G et al. Tumor molecular characteristics in patients (pts) with International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) good (G) and intermediate/poor (I/P) risk. Ann. Oncol. 29, viii306–viii307 (2018).
  Google Scholar
• 16. Albiges L, Tannir NM, Burotto M et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 5, e001079 (2020).
  MedlineGoogle Scholar
• 17. McDermott DF, Huseni MA, Atkins MB et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).
  Medline CASGoogle Scholar
• 18. Braun DA, Hou Y, Bakouny Z et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909–918 (2020).
  Medline CASGoogle Scholar
• 19. Au L, Hatipoglu E, de Massy MR et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell 39, 1497–1518.e11 (2021).
  Medline CASGoogle Scholar
• 20. Vano YA, Elaidi R, Bennamoun M et al. Nivolumab, nivolumab–ipilimumab, and VEGFR–tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 23, 612–624 (2022).
  Medline CASGoogle Scholar
• 21. Choueiri TK, Motzer RJ, Powles T et al. Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab+cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC). J. Clin. Oncol. 41, 608 (2023). •• Demonstrates an independent progression-free survival advantage of combination therapy (immune checkpoint inhibitor + tyrosine kinase inhibitor) regardless of PD-L1 and c-MET status.
  Google Scholar